Petra has several key collaborations in place to enable faster and more efficient drug discovery, speeding molecules into the clinic with greater confidence:
- In 2016, Petra entered into a collaboration and licensing agreement with Sprint Bioscience for the research, development, and commercialization of their PIP4K2 program targeting tumor metabolism. Petra has full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics.
- In 2017, Petra and Schrödinger LLC, a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, announced a multi-target research collaboration to develop novel therapeutics for the treatment of cancer and metabolic diseases. Through the collaboration, Petra will leverage Schrödinger’s computational drug discovery platform to design and develop new therapies for people with limited treatment options who suffer from cancer and metabolic diseases.